City University of New York (CUNY)

CUNY Academic Works
Publications and Research

Hunter College

2000

Epitope-Tagged P0Glycoprotein Causes Charcot-MarieTooth–Like Neuropathy in Transgenic Mice
Stefano C. Previtali
San Raffaele Scientific Institute

Angelo Quattrini
San Raffaele Scientific Institute

Marina Fasolini
San Raffaele Scientific Institute

Maria Carla Panzeri
San Raffaele Scientific Institute

Antonello Villa
San Raffaele Scientific Institute

See next page for additional authors

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/hc_pubs/178
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

Authors
Stefano C. Previtali, Angelo Quattrini, Marina Fasolini, Maria Carla Panzeri, Antonello Villa, Marie T. Filbin,
Wenhui Li, Shing-Yan Chiu, Albee Messing, Lawrence Wrabetz, and M. Laura Feltri

This article is available at CUNY Academic Works: https://academicworks.cuny.edu/hc_pubs/178
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Abstract. In peripheral nerve myelin, the intraperiod
line results from compaction of the extracellular space
due to homophilic adhesion between extracellular domains (ECD) of the protein zero (P0) glycoprotein.
Point mutations in this region of P0 cause human hereditary demyelinating neuropathies such as CharcotMarie-Tooth. We describe transgenic mice expressing a
full-length P0 modified in the ECD with a myc epitope
tag. The presence of the myc sequence caused a dysmyelinating peripheral neuropathy similar to two distinct
subtypes of Charcot-Marie-Tooth, with hypomyelination, altered intraperiod lines, and tomacula (thickened

myelin). The tagged protein was incorporated into myelin and was associated with the morphological abnormalities. In vivo and in vitro experiments showed that
P0myc retained partial adhesive function, and suggested
that the transgene inhibits P0-mediated adhesion in a
dominant-negative fashion. These mice suggest new
mechanisms underlying both the pathogenesis of P0
ECD mutants and the normal interactions of P0 in the
myelin sheath.
Key words: Charcot-Marie-Tooth disease • myelin
protein zero • tomacula • transgenic mice • Myc-tag

Introduction
Charcot-Marie-Tooth (CMT)1 is the most frequent hereditary peripheral neuropathy in humans. The most common
variant (CMT1A) is due primarly to the duplication of a
large region of chromosome 17 that includes the gene for
peripheral myelin protein-22 (PMP-22) (for review see
Harding, 1995). In other cases, CMT1 and the more severe
variants Déjérine-Sottas (DSS) syndrome and congenital
hypomyelination (CH) are due to point mutations of the
PMP-22, GJ␤1, myelin protein zero (MPZ), or EGR2
genes (reviewed in Nelis et al., 1999; Wrabetz et al., 2001).
Thus, similar clinical entities are due to mutations of different genes involved in a common pathway that normally
results in peripheral nerve myelination. However, different mutations in the same gene give rise to neuropathies of
varying severity. For example, mutations in the MPZ gene
may cause either CMT1B, DSS, or CH. These mutations
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are mostly localized in the extracellular domain (ECD) of
the protein zero (P0) glycoprotein, which is encoded by
MPZ (for review see Nelis et al., 1999).
P0, the most abundant protein in the peripheral nerve
(Lemke et al., 1988), is a single pass transmembrane protein
expressed in Schwann cells (SCs) that belongs to the immunoglobulin superfamily. P0 acts as a homotypic adhesion
molecule necessary for the formation of the intraperiod line
(IPL) as myelin lamellae compact (D’Urso et al., 1990; Filbin et al., 1990; Schneider-Schaulies et al., 1990; Giese et al.,
1992). Crystallographic analysis revealed that this adhesive
function is probably mediated by the interaction of tetramers composed of ECD of P0 molecules emanating from
apposing lamellae (Shapiro et al., 1996). The P0 null mouse
supports such a role for P0 and shows hypomyelination, widening and uncompaction of myelin lamellae, and slow nerve
conduction velocity (Giese et al., 1992; Martini et al., 1995).
The homozygous P0 null mouse is considered a model of patients with DSS that are homozygous for predicted null mutations (e.g., Gly74 frameshift; Warner et al., 1996). The
heterozygous P0 null mouse presents a late onset, mild neuropathy and is a model for patients with CMT1B that are
heterozygous for P0 loss of function mutations (for review
see Martini, 1997). However, it is likely that the majority of
P0 mutations act through gain of function, since, in most
cases, they are dominantly inherited and cause a more se-
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vere phenotype than that of the heterozygous P0 null mice
(for review see Martini, 1997). Furthermore, the fact that
some mutations may act through gain of function, and others through loss of function can explain, in part, the observation that mutations in the MPZ gene may cause either
CMT1B, DSS, or CH.
Here, we describe the first transgenic mice that model
CMT1B due to a gain of P0 function. These mice were created by adding a randomly inserted P0 transgene to two
normal P0 alleles to reveal only gain of function mechanisms. To follow intracellular trafficking of future P0 mutants, normal P0 was first tagged at the mature NH2 terminus in the ECD. Crystallographic studies suggested that
the NH2 terminus of P0 was not directly engaged in cis or
trans interactions (Shapiro et al., 1996). P0myc mice were
created in parallel with mice in which overexpression of
wild-type (wt) P0 causes a developmental delay in myelination (Wrabetz et al., 2000). Surprisingly, P0myc mice
showed clinical and morphological abnormalities that
were independent of P0 overexpression. The morphological abnormalities resembled two subtypes of CMT1B patient, and the abnormalities worsened after outcrossing
P0myc into the P0 null background. P0myc was detected in
abnormal myelin, and P0myc was partially adhesive, as
P0myc expressed in P0 null mice produced myelin with
only a slight widening of IPLs, and in vitro, P0myc aggregated transfected cells equally to wt P0. These data suggest
that P0myc acts by a dominant-negative gain of function
and have implications for normal P0 interactions in myelin.
P0myc mice support the idea that the pathogenesis of some
mutations in the ECD of P0 includes gain of function.

Materials and Methods
Transgenic Mice, Genomic Analysis, Breeding, and
Genetic Backgrounds
The transgene derives from mP0TOT (Wrabetz et al., 2000) that contains
the complete P0 gene with 6 kb of promoter, all exons and introns, and the
natural polyadenylation site (see Fig. 1). In mP0TOT(myc), an oligonucleotide encoding myc tag (5⬘-CCATTGAGCAAAAGCTCATTTCTGAAGAGGACTTGAATG-3⬘) was inserted in frame into the MscI site in P0
exon 2, corresponding to the NH2 terminus of the mature P0 protein (see
Fig. 1) and recreated the signal peptide cleavage site. The myc oligonucleotide was first inserted into the plasmid mP05.7 (Wrabetz et al., 2000) to
create mP05.7myc. A 7-kb EcoRI fragment was excised from the plasmid
mP0E (Wrabetz et al., 2000) and ligated into EcoRI-digested mP05.7myc
to generate the plasmid mP0TOT(myc). mP0TOT(myc) contains a polymorphic BglII site in exon 3 (amino acid sequence is conserved) that is not
present in the endogenous FVB/N P0 alleles. For oocyte injection, the
transgene was excised from the vector using XhoI and NotI. Transgenic
mice were generated by standard techniques (Brinster et al., 1985) using
fertilized eggs obtained from the mating of FVB/N mice (Taconic). Transgenic lines were maintained by backcrosses to FVB/N mice (Taconic or
Charles River). Founders that transmitted the transgene to progeny were
identified by Southern blot and PCR analysis of genomic DNA, which
were prepared from tail samples, as described previously (Feltri et al.,
1999; Wrabetz et al., 2000). The genetic designations of the three lines that
have been maintained from this study are: line 88.1,TgN(Mpzmyc)19Mes;
line 88.2,TgN(Mpzmyc)20Mes; and line 88.4, TgN(Mpzmyc)21Mes.
P0 null mice (P0 ⫹/⫺ and P0 ⫺/⫺) were identified by Southern blot and PCR
analysis of tail genomic DNA, as described (Wrabetz et al., 2000). P0 null
mice were backcrossed into the FVB/N background. The N5 generation
P0⫹/⫺ was crossed with transgene 88 (P0myc) FVB to obtain N6 P0⫹/⫺/
P0myc. Subsequent crosses of N6 P0⫹/⫺/P0myc with N6 P0⫹/⫺ gave rise to the
F1N6 generation that was analyzed for rescue, as a consequence of reduced
P0 dosage. P0⫹/⫺/P0myc and P0⫺/⫺/P0myc mice were identified by Southern
blot. The presence of a 2.1-kb band identified the null allele (Wrabetz et al.,
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2000), whereas the myc transgene was identified after densitometry and
PCR analysis by the presence of an intense 1.0-kb band. In P0⫺/⫺myc, the
6.8-kb band from the wt Mpz allele was absent (data not shown).
All the experiments involving animals were described in protocols approved by the San Raffaele Scientific Institute Institutional Animal Care
and Use Committee. Animals that showed signs of distress due to neuropathy were killed.

Electrophysiologic Analysis
The compound muscle action potential and nerve conduction velocity of
transgenic mice and control littermates at postnatal day (P) 42 were measured as described (Wrabetz et al., 2000).

Morphology
Transgenic mice and age-matched controls were killed at the ages indicated, and semithin and ultrathin morphological analysis were conducted
as previously described (Quattrini et al., 1996). To quantitate the amount
of abnormal myelin periodicity after crossing into the P0 null background,
at least 100 myelinated fibers for each genotype were counted at a magnification of 7,000⫻ in 10 random, independent fields; abnormally compacted fibers were expressed as the percent of total fibers.

Immunohistochemistry and
Immunoelectron Microscopy
For cryosections, sciatic nerve segments were fixed for 1 h in 4%
paraformaldehyde in 0.1 M PBS, cryoprotected in 20% sucrose, embedded in OCT (Miles), and snap frozen in liquid nitrogen. Indirect immunofluorescence was performed on transverse and longitudinal cryosections.
Cryosections (8-m thick) were fixed in cold acetone for 2 min, rinsed
twice in PBS, and blocked with 10% normal goat serum (Dako). Double
staining was performed with a rabbit pAb recognizing P0, (a gift from Dr.
D. Colman, Mount Sinai School of Medicine, New York, NY) (Colman et
al., 1982), and an mAb recognizing myc (American Type Culture Collection; clone 1-9E10.2), diluted 1:200 and 1:20, respectively. Sections were
then treated with FITC- or TRITC-conjugated secondary antibodies
(Southern Biotechnology Associates, Inc.), and examined with confocal
microscopy (MRC 1024; Bio-Rad Laboratories).
For electron microscopic immunocytochemistry, segments of sciatic
nerves were fixed with 4% paraformaldehyde and 0.25% glutaraldehyde
in 125 mM PBS, pH 7.4, for 2 h. The samples were infiltrated with polyvinylpyrrolidone and frozen in a 3:1 (vol/vol) mixture of propane and isopentane cooled with liquid nitrogen. Ultrathin cryosections (50–100-nm
thick) were cut using an Ultracut ultramicrotome, which was equipped
with a Reichert FC4 cryosectioning apparatus and processed as described
previously (Villa et al., 1993). In brief, the cryosections were collected over
nickel grids and covered with 2% gelatin. After treatment with 125 mM
PBS supplemented with 0.1 M glycine, they were double-immunostained
with primary antibodies anti-P0 and anti-myc diluted in PBS-glycine
buffer. Gold-labeled secondary antibodies (British Biocell International)
diluted 1:80 in PBS-glycine buffer recognized P0 (small particles, 5 nm) and
myc (large particles, 15 nm). Cryosections were then examined by EM.

Teased Fiber Preparation
Glutaraldehyde-fixed sciatic nerves from 6-mo-old P0myc transgenic mice
were osmicated and placed in glycerol. Single fibers were separated with fine
forceps, placed on slides, and analyzed with a light microscope (Olympus).

Semiquantitative Reverse Transcribed-PCR
Total RNA isolation and reverse transcription (RT)-PCR were performed, as
described previously (Wrabetz et al., 2000), on sciatic nerves from animals
from P28. The RT-PCR assay was performed as a modification of the method
by Fiering et al. (1995). The polymorphic BglII site spans the intron 2/exon 3
boundary, but in the cDNA product its four nucleotide (nt) core, a DpnII site,
is still present. The validity of the method for semiquantitative assessments
was verified using known amounts of templates, containing or not containing
DpnII (Wrabetz et al., 2000). In the rescue experiments, RT-PCR was used to
determine total levels of P0 mRNA in P28 sciatic nerves, as previously described (Feltri et al., 1999). In brief, equal volumes of RT products were amplified using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) specific
primers (5⬘-GTATGACTCTACCCACGG-3⬘ and 5⬘-GTTCAGCTCTGGGATGAC-3⬘) in the presence of ␣32P-dCTP. Aliquots from the amplification
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Figure 1. Design of P0myc transgene. A schematic representation of
the endogenous Mpz gene, the mP0TOT(myc) transgene, and the
mature P0myc protein are shown. ecd, ectodomain; tm, transmembrane domain; icd, intracellular domain. Coding portions of exons
are in black; the myc tag is hatched and marked by an asterisk.

were withdrawn at 22, 24, and 26 cycles, resolved on an acrylamide gel, and visualized by autoradiography. The intensity of the bands was quantified by
densitometry (Molecular Dynamics) to verify that amplification was logarithmic and to determine the relative amount of starting cDNA from each sample. Equal amounts of reverse transcribed product, as determined by the
GAPDH signal, were amplified using primers specific for P0 (5⬘-GTCCAGTGAATGGGTCTCAG-3⬘ and 5⬘-GCTCCCAACACCACCCCATA-3⬘).
The intensity of the bands was quantified by densitometry, and the ratio between P0 and GAPDH was determined.

Western Blot Analysis
Western blot analysis was performed, as described previously (Wrabetz et
al., 2000), on sciatic nerves from P28 transgenic and nontransgenic littermates. To verify equal loading of proteins, membranes were stained with
amido black. The primary antibodies used were: anti-myc (clone 1-9E10.2
ATCC), anti-P07 (a gift from Dr. J. Archelos, Karl-Franzens-Universitat,
Graz, Austria) (Archelos et al., 1993). Peroxidase-conjugated second antibodies (Sigma-Aldrich) were visualized using the enhanced chemiluminescence method (NEN Life Science Products).

Figure 2. Lines, clinical phenotype, and nerve conduction velocities (ncv) are listed in the table, ncv are in m/s expressed as mean ⫾
SEM (n ⫽ 2–4). In the photograph below, a P 0myc (Tg 88.2) animal at P160 manifests atrophy in axial and hindlimb muscles
compared with a normal age-matched control (non Tg). ⫺, absent; ⫹, mild; ⫹⫹, medium; and ⫹⫹⫹, severe.

The entire Mpz was reconstructed to contain 6 kb of the P0
5⬘ flanking sequence, all exons, the natural polyadenyla-

tion signal and 400 flanking nts (mP0TOT vector; Wrabetz
et al., 2000). A derivative of mP0TOT (mP0TOTAnlacZ)
was regulated in parallel with P0 during postnatal development and after Wallerian degeneration (Feltri et al., 1999).
Moreover, mP0TOT was able to produce structurally and
functionally normal myelin when expressed in the P0⫺/⫺
background (Wrabetz et al., 2000). To locate P0 intracellularly, sequence encoding a myc tag was inserted into exon
2 (mP0TOTmyc), downstream of the sequence coding for
the signal peptide, to precede the NH2 terminus in the extracellular portion of the mature protein (Fig. 1).
We produced four founder P0myc mice, three of which
(88.1, 88.2, and 88.4) transmitted the transgene to offspring. Mice from all lines displayed tremors and variable
signs of muscle weakness, such as clenching of the paws,
dragging of hind limbs, and floppy tail (Fig. 2). One line
(88.2) manifested self-mutilation, presumably deriving
from sensory symptoms. In two of the three lines (88.1 and
88.2), a marked muscular atrophy was evident (Fig. 2). All
symptoms were most severe in line 88.2, intermediate in
line 88.1, and least severe in line 88.4, corresponding to
copy number and expression of the transgene, as estimated by Southern blot and RT-PCR analysis (see below
and data not shown).
Since these symptoms are characteristic of a peripheral
neuropathy, we measured nerve conduction velocity,
which was significantly decreased in both lines tested (Fig.
2). These data indicate that the mice suffer from a dysmyelinating peripheral neuropathy.
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Aggregation Assay
To construct the pSJLrP0myc plasmid, a MscI/BstE II fragment from plasmid mP05.7 myc was first cloned into rP0pBSK⫹ (Filbin and Tennekoon,
1990). The P0myc cDNA was then cloned into the XhoI site of pSJL (Filbin and Tennekoon, 1990) to create pSJLP0myc. The hybrid cDNA used
in transfection encodes a P0myc with one conservative amino acid change
relative to rat (val9ile; residue nine is ile in the mouse and val in rat and
human); no mutations have been described at human P0 val9. CHO cell
transfection, expression, and adhesion essays were described previously
(Filbin et al., 1990; Filbin and Tennekoon, 1993). In brief, a single cell suspension of P0, P0myc, or control cells was allowed to aggregate during
rocking at 5 rpm at 37⬚C. Aggregate formation in samples withdrawn at
various times was assessed by microscopic examination and by counting
total particle number in a Coulter counter. Reduced total particle number
is an indication of aggregate formation. The mixed adhesion assay was
carried out as described previously (Wong and Filbin, 1996).

Image Analysis
Micrographs of morphological samples and radiographic films were digitalized using an AGFA Arcus 2 scanner and figures were prepared using
Adobe® Photoshop 5.0.

Results
Transgenic Mice Expressing P0myc Develop a
Dysmyelinating Peripheral Neuropathy

Figure 3. P0myc nerves contain abnormal myelin compaction and tomacula. (A–C) Semithin section, (D) teased fiber, and (E–I) ultrastructural analysis of (A) wt, (B–G) P0myc/Tg 88.1, and (H and I) P0myc/Tg 88.2 sciatic nerves showing dysmyelination, tomacula, and widening of
myelin lamellae. Transverse semithin sections stained with toluidine blue at (A and B) P28 showed diffuse hypomyelination and few abnormally outfolded myelin sheaths in P0myc mice (tomacula-like). (C) At 7 mo, hypomyelination was still severe and the number of myelin out-
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Figure 4. mP0TOT(myc) transgene expression in sciatic nerve.
Semiquantitative RT-PCR analysis from P28 sciatic nerves for
endogenous Mpz and transgenic mRNA. Total RNA was reverse
transcribed and the product amplified by PCR, using a primer
pair that recognized identically both endogenous nontransgenic
(Tg⫺) and transgenic (Tg88 and Tg80) P 0 cDNA. Due to a polymorphism present only in transgenic P 0, it is possible to distinguish bands of endogenous P0 cDNA (326 nt) from transgenic P 0
cDNA (244 and 82 nt) after DpnII digestion. The relative proportion of transgenic and endogenous mRNA is shown, and the
“-fold overexpression” is the quotient of the transgenic divided
by the endogenous signal. This experiment shows that the transgenic mRNA is expressed in all lines. Note that the P 0myc/Tg88.4
ratio is similar to P0wt-overexpressing/Tg80.3 line, which expresses below the threshold at which dysmyelination appears.

P0myc Mice Resemble Subtypes of CMT1B
Morphological analysis of transgenic sciatic nerves at P28
showed hypomyelination, with thin or absent myelin
sheaths on many large caliber axons, both at the light- and
electron-microscopic levels (Fig. 3, B and F). Occasional fibers showed thick and redundant myelin, possibly representing myelin outfolding or tomacula. Ultrastructural analysis revealed that the myelin lamellae were widely spaced,
in particular, the inner lamellae closer to the axon (Fig. 3
H). High magnification of the poorly compacted areas revealed absence of the IPL (inset). Occasionally, the major
dense line (MDL) was also uncompacted. Similar packing
abnormalities, especially at the innermost part of the myelin
sheaths, have been described in several CMT1B patients
carrying missense mutations in the ECD of P0 (GabreelsFesten et al., 1996; Kirschner et al., 1996b; Ohnishi et al.,
1999). At seven months, the hypomyelination was more
pronounced, with most of the large caliber axons showing
very thin or absent myelin (Fig. 3 C). Several axons were
enlarged and completely devoid of myelin (Fig. 3, C and G),
whereas unmyelinated fibers appeared normal. In parallel,
tomacula were more frequent (Fig. 3 C, inset). In teased fiber analysis or EM, the tomacula appeared to originate
from the paranodal region (Fig. 3, D and E) and contained
poorly compacted myelin (Fig. 3 I). Axonal caliber was pre-

served throughout the tomacula (Fig. 3 E). Similar tomacula were reported in a different group of CMT1B patients
with mutations in the ECD of P0 (Thomas et al., 1994;
Gabreels-Festen et al., 1996; Tachi et al., 1997; Nagakawa et
al., 1999; Planté-Bordeneuve et al., 1999; Sindou et al.,
1999). Hypomyelination, tomacula, and uncompaction of
the myelin sheath were readily observed in all three P0myc
lines. Occasionally, demyelinating figures, short internodes
suggesting remyelination, and signs of axonal degeneration
were observed in older mice (data not shown). In contrast,
we never observed the presence of onion bulbs at any age in
the P0myc mice. Thus, it appears that the myc tag at the
NH2 terminus of the mature P0 protein mimics some of the
effects of P0 mutations in the ECD.
Since P0myc mice potentially overexpress P0, we compared
the morphology of mice expressing P0myc (Tg 88) to mice
overexpressing P0wt (Tg 80; Wrabetz et al., 2000). Whereas
widening of myelin lamellae and tomacula were present in all
three P0myc lines, we never observed them in any P0wt insertion (eight independent insertions were examined for tomacula; of these, four were also examined for widened lamellae).
Therefore, the morphological findings of P0myc mice were
distinct from those of P0wt overexpressor mice.

The Phenotype of P0myc Mice Is Independent of
P0 Overexpression
To determine the levels of mP0TOT(myc) mRNA expression, we used RT-PCR analysis and exploited a DpnII polymorphism present in the transgenes, but not in endogenous
Mpz. P0 primers flanking the polymorphism amplify a 326nt band from reverse transcribed sciatic nerve mRNA. After DpnII digestion, the 326-nt band corresponding to the
endogenous P0 remains uncut, whereas the transgenic P0
cDNA is cleaved into two bands of 244 and 82 nt (Fig. 4).
We have previously shown that at ⵑ0.5-fold overexpression of P0 above normal levels in transgenic mice, a dosedependent dysmyelination appears (hypomyelination and
SC developmental delay) (Wrabetz et al., 2000). To confirm that the observed phenotype in P0myc mice was not
due to P0 overexpression, we compared P0 expression levels in P0myc and P0wt lines. We chose the P0 line (80.3) that
is just at the threshold of 0.5-fold P0 overexpression necessary to cause dysmyelination. After DpnII digestion, the
two bands of 244 and 82 nt, corresponding to the transgenic mRNA, were seen in all the P0myc (88) and P0wt
(80.3) lines, but not in nontransgenic mice (Fig. 4). The
326-nt band corresponding to endogenous P0 mRNA is
seen in all samples. Densitometry revealed that P0myc
lines 88.1, 88.2, and 88.4 expressed P0myc at 2.5-, 4-, and
0.4-fold above the level of endogenous Mpz, whereas the
P0wt line (80.3) expressed 0.3-fold (0.3–0.5-fold in other
experiments, data not shown) of endogenous Mpz. Therefore, line 88.4 expresses at levels just at the threshold necessary to reveal an overexpression phenotype, yet it has
the more severe phenotype similar to the other P0myc

folding/tomacula rose (inset). Some axons appear enlarged and devoid of myelin (see also G). Teased fiber and electromicroscopic analysis of
longitudinal sections at (D) 12- and (E) 7-mo-old in P0myc showed that tomacula often originate at the paranodal region (arrow), and that the
axon caliber is preserved underneath the tomacula. EM showed axons with absent or thin myelin sheaths at (F) P28 and demonstrated (H and
inset) widely spaced myelin lamellae in many fibers. In 7-mo-old animals, hypomyelination, (G) enlarged amyelinated axons, and (G and I)
myelin outfolding/tomacula containing poorly compacted myelin were prominent, whereas (I, asterisk) unmyelinated fibers appeared normal.
Bar (in C): (A–C) 65 m; (inset) 40 m. Bar (in I): (D) 25 m; (E) 3.5 m; (F) 3 m; (G) 5 m; (H) 1 m; (inset) 0.6 m; (I) 6 m.
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Figure 5. P0myc protein expression in sciatic nerve. Western blot
analysis performed on sciatic nerve lysates from P 0myc/Tg 88,
P0wt/Tg 80.3, and nontransgenic/Tg(⫺) mice at P28. Anti-myc
antibody recognized P0myc only in P0myc/Tg 88 nerve lysates
(top), whereas anti-P0 antibody recognized both P0myc and P0wt
(bottom). The amount of P0 reflects the effect of transgene overexpression (88.2 ⬎ 88.1 ⬎ 88.4) counteracted by the loss of P 0 due
to dysmyelination (88.2 ⬎ 88.1 ⬎ 88.4). A relative molecular
weight of 30 kD is indicated.

lines. A further reduction of transgene dosage, achieved by
outcrossing the P0myc/88.4 line with P0 null mice (to obtain
P0myc/P0⫹/⫺ and P0myc/P0⫺/⫺mice) improved the hypomyelination, but not the widening of myelin lamellae and
tomacula (see Fig. 7, and below). These data, taken together with the presence of morphological signs distinct
from P0-overexpressing mice, confirm that the phenotype
of P0myc mice is not due to overexpression of P0.

P0myc Protein Is Expressed in Transgenic
Mouse Nerves
To evaluate if the transgenic protein was expressed in
P0myc mice, we performed Western blot analysis on sciatic
nerve homogenates. Anti-myc antibody detected a band of
ⵑ33 kD, the appropriate size for P0 plus myc, in all of the
P0myc lines, but not in nontransgenic littermates or in P0wt
mice (Fig. 5). In the P0myc/88.2 line, the total levels of P0
were reduced in association with the loss of bulk myelin, as
previously found in P0wt mice (Wrabetz et al., 2000). Endogenous P0 was detected in all lanes using an anti-P0
mAb; a larger band, corresponding to P0myc, was again
detected only in the P0myc/88 lines. The smaller band seen
with anti-myc, and sometimes with the anti-P0 antibody, is
probably a degradation product (Wrabetz et al., 2000).
Amido black staining showed that comparable amounts of
protein homogenates were loaded in each lane (data not
shown). These data demonstrate that the transgenic protein was expressed in sciatic nerves of all lines.

P0myc Protein Is Incorporated in the Myelin Sheath and
Present in Widened Lamellae and Tomacula
Since P0myc mice contain two normal Mpz alleles in addition
to the transgene, and mP0TOT(myc) is expressed at the level
of mRNA and protein in transgenic sciatic nerves, P0myc
should exert its negative effect by a gain of function rather
than a loss of function mechanism. If this is true, the myctagged P0 should not only be expressed, but should also be incorporated in the myelin sheath, and possibly present in the
pathological fibers. To test this, we first stained transgenic sciatic nerves by immunohistochemistry using P0 pAb and myc
mAb. By double immunofluorescence and confocal microsThe Journal of Cell Biology, Volume 151, 2000

Figure 6. P0myc is correctly inserted into myelin sheaths, in parallel
with P0wt. (A and B) Merged confocal images and (C) immunoelectron microscopy of P28 P0myc/Tg 88.4 sciatic nerves cut (A and C)
transversely or (B) longitudinally, and double stained with anti-myc
(TITC or large gold particles) and anti-P0 (FITC or small gold particles) antibodies. (A and B) Almost complete colocalization of the
two signals was observed after merge (in yellow). Rare fibers did not
stain for myc (e.g., green signal, asterisk). (C) Immunoelectron microscopy showed that P0myc was present in areas containing widened myelin lamellae.

copy, we observed both P0 (green fluorescence) and myc (red
fluorescence) in compact myelin, and the signals often colocalized (Fig. 6 A). Longitudinal sections showed that myc was
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Figure 7. Myelin uncompaction and tomacula are not rescued in the Mpz null background. P0myc/Tg 88.4 was crossed into the Mpz heterozygous and homozygous null background, and sciatic nerves from P28 offspring were analyzed. Semithin sections of (A) Tg 88.4 (P 0myc), (B) Tg
88.4/P0⫺/⫺, (C) Tg 88.4/P0⫹/⫺, (D) Tg 80.4 (P0wt), (E) Tg 80.4/P0⫺/⫺, and (F) P0⫺/⫺ show that, whereas lowering the dosage of P0 rescues dysmyelination in Tg80 (P0wt overexpressor) mice (compare D to E), it exacerbates tomacula in Tg 88 (P 0myc) mice (B and C, arrows). EM analysis
of the myelin sheaths (in each case, the area of the best “compaction” is shown) of (G) nontransgenic, (H) Tg 88.4/P 0⫹/⫺, (I) Tg 88.4/P0⫺/⫺, (J)
P0⫺/⫺ reveals that when P0myc is expressed (I) alone it can compact myelin lamellae, however in I the space of 10 periods (11 MDL marked by
white circles) is larger than that formed by (G) P0wt or a mixture of (H) P0myc and P0wt. 10 periods ⫽ 156 ⫾ 2.3 nm (mean ⫾ SEM) in G (n ⫽
9) and 175 ⫾ 4.6 nm in I (n ⫽ 8), P ⬍ 0.001 by Student’s t test, which is equivalent to a 12% increase. Increasing the magnification, such that
the double IPLs are visible, shows that this increase is due to a widened space between IPL in I compared with G (data not shown). Note that
in contrast to what was reported previously in P0⫺/⫺ mice on an inbred mixed 129Sv/C57BL/6J background (Giese et al., 1992), in (J) P0⫺/⫺
FVB congenic mice, most fibers do not form either IPL or MDL. (K) Semiquantitative RT-PCR analysis from P28 sciatic nerves shows that
total levels of P0 mRNA are reduced in Tg 88.4/P0⫹/⫺ compared with nontransgenic or P0myc/Tg 88.4 nerves. Relative expression (rel. exp) is
the quotient of the densitometric values of P0 divided by GAPDH; the quotient obtained in the nontransgenic (Tg ⫺) is arbitrarily defined as
one. (L) Digestion with DpnII allows endogenous (326-nt band) and transgenic (244- and 82-nt bands) P 0 signals to be distinguished. The level
of endogenous P0 is decreased out of proportion in Tg 88.4/P0⫹/⫺ (predicted ratio of P0myc/P0 ⵑ50:50, not 80:20), suggesting that P0myc has a
dominant-negative effect on the expression of endogenous Mpz. Bar: (A–F) 50 m; (G–J) 60 nm.

present in enlarged fibers (Fig. 6 B). The majority of fibers
expressed P0myc. A few fibers, apparently normal in caliber,
expressed only wt P0 (Fig. 6 A, asterisk).
To determine if P0myc protein was present in the uncompacted myelin lamellae, we performed double immu-

noelectron microscopy for P0 and P0myc. Fig. 6 C shows
that both P0 (small gold particles) and P0myc (large gold
particles) are present in the widened myelin lamellae.
Both P0 and P0myc were found in normal myelin, as well.
Thus, the transgenic protein is incorporated into the ma-
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Figure 8. Aggregation properties of P0myc-expressing cells. Single
cell suspensions of CHO cells expressing P0wt, P0myc, and control
transfected cells were allowed to aggregate. Samples were withdrawn at intervals and the total particle number was counted in a
light microscope. The mean percent of initial total particle number ⫾ SEM (n ⫽ 3) was plotted against time. Cells transfected with
P0myc aggregated identically to those transfected with P 0wt.

jority of myelin sheaths, and it is present both in tomacula
and widened myelin lamellae. Furthermore, though antiP0 antibodies recognize epitopes on both P0 and P0myc,
P0myc is not likely to account for all of the P0 staining detected, as Western blot analysis revealed similar amounts
of P0 and P0myc in nerves of this line (P0myc/88.4), and immunohistochemical analysis showed that only rare fibers
contained P0 alone. Thus, it is very likely that P0 and
P0myc are cointegrated in most myelin sheaths.

The Phenotype of P0myc Mice Is Not Rescued by
Decreasing or Removing wt P0
To analyze the effect of P0myc in the absence of P0wt, we
crossed the P0myc/88.4 line into the P0 null background
and analyzed sciatic nerves at P28. A similar experiment
performed in a line of mice that overexpressed comparable levels of wt P0 (Tg80.4; Wrabetz et al., 2000) completely rescued the hypomyelination due to P0 overexpression (compare Fig. 7, D and E). In contrast,
hypomyelination is only slightly improved for P0myc in either the P0⫹/⫺ or P0⫺/⫺ backgrounds (compare Fig. 7, B
and C to A). More strikingly, tomacula and abnormal
compaction (see below) were not improved by lowering
the dosage of P0, rather they worsened. Tomacula were
rarely seen at P28 in cross sections of P0myc/P0⫹/⫹ mice,
but were readily observed in cross-sections of P0myc/P0⫹/⫺
and P0myc/P0⫺/⫺ mice (Fig. 7, B and C, arrowheads).
Nerve conduction velocities also remained low in two
P0myc lines in the P0⫹/⫺ background (88.4 and 88.1; Fig. 2).
These data strongly suggest that abnormal compaction of
myelin, tomacula, and low nerve conduction velocities are
due to the presence of P0myc.
The kind of compaction abnormalities seen in these experiments provided insight into the mechanism by which
P0myc causes dysmyelination. The proportion of myelinated fibers with abnormally compacted myelin was
ⵑ11% in P0myc/P0⫹/⫹, 35% in P0myc/P0⫹/⫺, and 100% in
P0myc/P0⫺/⫺ mice. We observed two types of abnormally
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compacted fibers in P0myc/P0⫺/⫺: (a) rare fibers in which
both the intraperiod and MDL were absent (data not
shown) and (b) majority of fibers with myelin that appeared compacted, but had abnormal periodicity due to a
wide (but not absent) IPL (Fig. 7, compare I to G). In contrast, most fibers of P0⫺/⫺ mice in the FVB congenic background formed neither an IPL, nor a MDL (Fig. 7 J).
These data suggest that P0myc molecules are partially adhesive, since they can interact homotypically to form an
IPL, but they are not able to compact it tightly.
We noticed that in the P0myc/P0⫹/⫺and P0myc/P0⫺/⫺
mice the myelin sheaths were thinner than normal. Such
hypomyelination could reflect either mild overexpression or reduced expression of P0, since in the FVB/N
background, P0⫹/⫺ showed slight hypomyelination at P28
(Wrabetz et al., 2000). To distinguish between these two
possibilities, we compared total P0 mRNA levels in nontransgenic, P0myc, and P0myc/P0⫹/⫺ sciatic nerves by semiquantitative RT-PCR. Fig. 7 K shows that the total levels
of P0 mRNA were reduced more than expected in P0myc/
P0⫹/⫺ sciatic nerves compared with nontransgenic and
P0myc nerves (expected relative expression should be
roughly one). This indicates that the hypomyelination in
P0myc/P0⫹/⫺ mice is likely due to underexpression of P0.
To understand why the total level of P0 mRNA in P0myc/
P0⫹/⫺ was reduced, we digested the RT-PCR product with
DpnII to distinguish the contribution of transgenic P0 versus wt P0 to the observed levels. Fig. 7 L shows that the levels of endogenous P0 are decreased out of proportion in
P0myc/P0⫹/⫺ nerves, suggesting that P0myc interferes not
only with P0 adhesion, but also with the expression of endogenous P0.

P0myc Protein Is Adhesive in an Aggregation Assay
In Vitro
Despite the severe phenotype of P0myc mice, myelin is
more compacted in P0myc/P0⫺/⫺ mice than in P0⫺/⫺ mice,
suggesting that the P0myc protein is at least partially adhesive. To measure the adhesiveness of P0myc, we expressed
the P0myc protein in CHO cells and measured its homotypic adhesion and compared it with wt P0. Fig. 8 shows
that P0wt and P0myc are equally adhesive in this assay. To
ask if P0myc could adhere to P0wt, we mixed P0wt- and
P0myc-expressing cells and examined the composition of
aggregates. The aggregates had an equal distribution of
P0myc and P0wt cells (data not shown; Filbin, M.T., manuscript in preparation). Therefore, P0myc retains the ability
to mediate homotypic interaction, and it adhered with the
same affinity to itself and to P0wt.

Discussion
Here, we describe the behavioral, electrophysiological,
and morphological alterations of transgenic mice carrying
an epitope (myc) tag at the NH2 terminus of the P0 glycoprotein, along with normal P0. Surprisingly, P0myc mice
manifested peripheral nerve abnormalities typical of two
subtypes of CMT1B, including tomacula and disruption of
IPLs. This phenotype differed from that of P0 overexpression and was not rescued in P0myc/P0 null mice. P0myc
acted via gain of function, as it was incorporated into myelin and present in morphological abnormalities. In addi-
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tion, P0myc was adhesive, as it aggregated transfected cells
equally to wt P0. These data underline that P0 structural interactions in myelin are complex and provide insights into
the normal role of P0 in myelin compaction. P0myc mice
provide the first model of CMT1B due to gain of function
and prove that myelin packing abnormalities result from
either loss or gain of P0 function.

Pathological Findings in P0myc Mice Are Due to the
Expression of the mP0TOT(myc) Transgene
The pathological features observed in P0myc mice could
be due to the ectopic expression of the transgene or, since
the peripheral nerve myelination is highly susceptible to
increased Mpz dosage (Wrabetz et al., 2000), to overexpression of P0. The observed phenotype is not due to ectopic expression, since a transgenic vector with the same
regulatory sequences of mP0TOT(myc) was expressed
with the same cell and developmental specificity as endogenous P0 (Feltri et al., 1999), and an identical transgene,
but without a myc tag, could produce morphologically normal myelin (Wrabetz et al., 2000).
In addition, tomacula and widened lamellae in P0myc
mice are not due to increased Mpz dosage. First, they persist independently from the total levels of P0. Second, they
are observed in the absence of pathological P0 overexpression: dysmyelination appears at ⵑ0.5-fold overexpression
(Wrabetz et al., 2000) and the P0myc/88.4 line showed mild
overexpression (0.4-fold), which is compatible with normal PNS myelination. A further reduction of total P0 by
breeding P0myc/88.4 into P0⫹/⫺ or P0⫺/⫺ backgrounds did
not rescue myelin uncompaction and tomacula or altered
conduction velocities. Finally, neither myelin uncompaction nor tomacula were ever observed in multiple lines of
transgenic mice overexpressing P0wt over a wide range.

P0myc Is Partially Adhesive
In vitro assay showed that P0myc and P0 are equally adhesive. However, when P0myc was the only P0 present in the
myelin sheath (P0myc/P0⫺/⫺ mice), it only partially compacted myelin lamellae. One interpretation of these results
is that P0myc is partially adhesive due to gain of abnormal
function. P0 emanates from the membrane as a tetramer
and each tetramer interacts in trans with four surrounding
tetramers protruding from the opposite membrane (Shapiro et al., 1996). These interactions involve several
ectodomains, in particular the BC loop (Shapiro et al.,
1996) and residue tryptophan 28, which is thought to interact directly with the apposing lipid bilayer (Shapiro et al.,
1996). The combination of these interactions are thought
to determine the spacing of the IPLs (Shapiro et al., 1996).
In this model, the NH2 terminus is apposed to the BC loop
such that the myc tag attached to the NH2 terminus could
impair interactions between this region and opposing tetramers, as well as tryptophan 28 with the lipid bilayer
(Shapiro et al., 1996), leading to widening of the IPL. In
agreement with this, we show that IPLs formed by myc in
P0myc/P0⫺/⫺ mice are larger than those formed by P0wt.
Although partially defective, P0myc could still permit initial adhesion between membranes in the cell assay, yet interfere with tight compaction as it normally occurs in myelin. Although the space between extracellular leaflets in
apposing myelin lamellae varies with fixation (King and
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Thomas, 1984; Kirschner et al., 1996a), the space between
membranes in adherent P0-transfected cell lines is probably consistently larger than the space found in compact
myelin (D’Urso et al., 1990; Filbin et al., 1990; Spiryda,
1998; Yin et al., 2000).
The putative impaired adhesiveness of P0myc may actually protect against P0 overexpression. High overexpression
of P0 causes dysmyelination due to abnormal appearance of
P0 in the spiraling mesaxons, resulting in obligate homotypic interactions and arrested myelination (Yin et al.,
2000). In contrast, this was never observed in line P0myc/
88.2, despite similar levels of transgenic P0 overexpression.
This also supports that P0myc is less adhesive than P0wt.

“Dominant-Negative” Is the Predominant Pathogenetic
Mechanism: Implication for the Formation of IPL and a
Normal Role of P0 in Myelin Compaction
Our data allow us to speculate whether P0myc acts
through a mechanism of loss or gain of function, and,
within gain of function, whether it is dominant-negative or
toxic. These distinctions are important, since different
mechanisms might imply different therapeutic approaches
for P0 ECD mutations in CMT1B patients.
Loss of function of P0myc cannot be the pathogenetic
mechanism, since P0myc mice contain two normal Mpz alleles. Furthermore, RT-PCR and Western blot analysis
showed normal amounts of P0wt mRNA and protein in
P0myc mice. For the mP0TOT(myc) transgene to act via
gain of function, it must be expressed. Immunolocalization
demonstrated that P0myc was expressed in myelinating SCs,
inserted in the myelin sheaths, and associated with widened
myelin lamellae and tomacula. Although anti-P0 antibodies
recognize both P0wt and P0myc, it is reasonable to assume
that P0 and P0myc colocalize. In fact, Western blot analysis,
in which wt and mutated protein are distinguishable by size,
showed a comparable amount of wt and P0myc protein in
lines 88.4 and 88.1 (Fig. 5). Since P0myc is detected in most
myelin sheaths (one rare exception is the green fiber shown
in Fig. 7 B), the expression of P0wt in these cells is presumably comparable. Thus, mP0TOT(myc) acts through gain of
function at the cellular level.
Our data suggests that P0myc does not act through a
toxic mechanism. If toxicity was the primary mechanism at
work, the effect of P0myc should increase in parallel with
its dosage and should be independent of the amount
of P0wt. Instead, we observe the opposite, suggesting that
P0myc behaves as a dominant-negative. Since P0myc and
P0wt colocalize in myelin, and an in vitro assay shows that
they can adhere to each other, P0myc probably have a
dominant-negative effect both on P0wt and itself.
Finally, we provide evidence that P0myc also decreases
P0wt mRNA levels. By outcrossing P0myc/88.4 line into the
P0⫹/⫺ background we expected to decrease the amount of
wt P0 message by one half, but we observed that it fell instead to one eighth. This suggests that P0myc may directly
exert a negative effect on the expression of Mpz. The
mechanism underlying this finding is presently unknown.

P0myc As a Model of Subtypes of CMT1B
The phenotype of P0myc mice is characterized by distal atrophy, tremor, low nerve conduction velocity, and dysmyelination with widening of myelin lamellae and tomacula.
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P0myc mice into the P0 null background shows that the
phenotype is worsened as the relative amount of P0wt is
lowered. Hence, increasing the dosage of P0wt could counteract the effect of the mutated P0, as long as the threshold
of overexpression that causes dysmyelination is not exceeded. This threshold is relatively low during development (Wrabetz et al., 2000), but reflects the effects of
abnormal expression of P0 in an early phase of myelinogenesis (Yin et al., 2000). Instead, the threshold for abnormalities may be higher when P0 overexpression begins in
adulthood.

Similar pathological findings are described in two subgroups of patients affected by CMT1B due to mutations
in the ECD of P0. Nerve biopsies of these patients usually manifest either myelin uncompaction or tomacula
(Gabreels-Festen et al., 1996). Abnormalities of myelin
compaction are found in substitution Arg69Cys, Arg69His,
Thr5Ile, and ⌬Ser34 (Gabreels-Festen et al., 1996; Kirschner et al., 1996b; Ohnishi et al., 1999). Usually in these patients, both IPL and MDL are absent, but in some cases the
IPL is predominantly affected (Arg69His and Arg69Cys)
(Kirschner et al., 1996b; Ohnishi et al., 1999). Instead,
other mutations, including Ile33Phe, Ser49Leu, Lys67Glu,
Asn93Ser, Lys101Arg, Asn102Lys, and Ile106Leu, result
in demyelinating neuropathy associated with focally abnormal folded myelin or tomacula (Thomas et al., 1994;
Gabreels-Festen et al., 1996; Nagakawa et al., 1999; PlantéBordeneuve et al., 1999; Sindou et al., 1999).
Of note, three of the point mutations in P0 ECD causing
tomacula involve residues (101, 102, and 106) present in
the FG loop, which also resides in proximity of the NH2
terminus (Shapiro et al., 1996). The FG loop does not appear to be involved in P0 homotypic interaction (Shapiro
et al., 1996) and, therefore, could be free to perform a different function (e.g., putative interaction with PMP-22, see
below), that, if perturbed, leads to tomacula formation. Interestingly, as mentioned before, point mutations in
CMT1B usually result in either myelin packing abnormalities or tomacula, but usually not both (Gabreels-Festen et
al., 1996). Thus, 13 amino acids of myc at the NH2 terminus of P0 could disrupt interactions of multiple domains of
P0 situated nearby (e.g., the BC and FG loops), resulting in
both packing abnormalities and tomacula.
Tomacula formation or abnormal myelin focal folding is
rare in CMT1B, whereas it is more common in CMT1A
and HNPP (Windebank, 1993). In mice, a tomaculous neuropathy is observed after inactivation of Pmp-22, myelinassociated glycoprotein (Mag), or periaxin genes (Adlkofer et al., 1997; Carenini et al., 1997; Yin et al., 1998;
Gillespie et al., 2000), and, in this report, in mutation of
Mpz. Since deletion or overexpression of P0 does not result in tomacula formation, it is more likely that an acquired function of P0myc could cause hypermyelination.
Recently, evidence for physical interactions between P0
and PMP-22 has been proposed (D’Urso et al., 1999), suggesting that P0myc may have a trans-dominant–negative
effect on PMP-22.
In this light, it is interesting to note that Roussy-Levy
syndrome, often due to PMP-22 duplication (Thomas et
al., 1997), can also be due to a mutation in the ECD of P0
(Asn102Lys). Nerve biopsies from these patients reveal
focally folded myelin sheaths and often absence of onion
bulbs (Planté-Bordeneuve et al., 1999). Roussy-Levy patients were originally considered distinct from CMT because of a particular combination of clinical symptoms including tremor, ataxia, and distal atrophy. Since P0myc
mice present with tremor, distal atrophy, probable sensory
symptoms (self-induced skin lesions), focally folded myelin, and no onion bulbs, they could be considered a model
of Roussy-Levy syndrome.
In summary, our data suggest that P0myc mice could
provide insights into the pathogenesis and treatment of a
subgroup of CMT patients. Interestingly, our data already
suggest a potential therapeutic approach. Crossing of
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